A Phase 2 interventional study of Low erythrodiol dose and Medium erythrodiol dose in Atherosclerosis Cardiovascular Disease, sponsored by Spanish National Research Council. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Spanish National Research Council · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Atherosclerosis with a site in Spain — 10 open to participants now, 25 under way, 12 of them phase 3. Atherosclerosis · Spain.
Among the 61 studies in Atherosclerosis with a site in Spain, this one is the 41st largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 3 of the 24 other live ones, and was the 56th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →10 of the 61 studies in Atherosclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Australia and 4 more countries
Ages 45–80
Instituto de Investigación Hospital Universitario La Paz · Sites in Spain
Ages 50+
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 50+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 25 more countries
Ages 18+
Instituto de Investigación Biomédica de Salamanca · Sites in Spain, France, Netherlands
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 20 · Phase 4 3
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 969 across the 41 interventional studies, 255 across the 20 observational. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 61 have an industry lead sponsor. The 10 most frequent:
Spanish National Research Council is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Spanish National Research Council has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT06958315Novartis PharmaceuticalsInclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Atherosclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:
Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?
Researchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses.
Participants will:
Attend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol
Undergo serial postprandial assessments over several hours, including:
Blood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events
The present project builds on previous studies in which we suggested that erythrodiol, a bioactive component of pomace olive oil, is capable of helping prevent cardiovascular diseases when administered as part of pomace oil, through the inhibition of atherosclerosis development.
A total of 22 adult volunteers, both women and men (18-40 years old), healthy and of normal weight, will be selected. Participants will be recruited in two phases.
In the first phase, recruitment will take place at Pablo de Olavide University. Inclusion criteria for this phase include: age between 18 and 40 years; body mass index (BMI) between 18.5 and 24.9 kg/m²; ability to provide informed voluntary consent; and willingness to comply with all study procedures. Candidates will be excluded if, at the time of recruitment, they exhibit any of the following: presence of any type of pathology (digestive, metabolic, endocrine, infectious, neoplastic, etc.) or food-related allergies or intolerances. Individuals taking any type of medication-except contraceptives-will also be excluded, as well as pregnant or breastfeeding women, and anyone who has participated in a clinical trial involving an investigational product within the past 60 days or is currently enrolled in a clinical trial. Furthermore, any person with a physical or intellectual limitation that, in the investigator's opinion, could prevent adherence to and completion of the protocol will be excluded. In this phase, only clinical history, age, weight, and height data will be collected.
In the second phase, only those subjects whose complete biochemical and hematological analyses produce results within normal ranges will be included in the study.
At the Virgen del Rocío Hospital (Seville), and after a 12-hour fast, three experiments will be conducted. In each of them, participants will be administered pomace olive oil containing different concentrations (low, medium, or high) of erythrodiol, the protective agent, in an amount of 50 g on each occasion. On the study day, blood samples will be taken (between 6 and 24 mL per draw and 90 mL total), 15 minutes before (baseline) and every hour for 6 hours after ingestion of a meal rich in the corresponding pomace oil. The meal will be accompanied by coffee (black, without sugar) or skimmed milk and whole-grain toast (3 slices). The consumption of these foods carries no health risk.
Venous access will be obtained by puncture with an Abbocath® catheter fitted with a Smartsite™ valve (Ivac®, Spec-Sets®) and a Vacutainer® system for sterile Hemogard® tubes with a silicone separator. This procedure involves only the risks inherent to simple blood sampling.
Part of the collected samples will be processed at the Clinical Analysis Laboratory Service of the Virgen del Rocío University Hospital for biochemical analysis, while another portion will be sent to the Instituto de la Grasa-CSIC.
In addition to these analyses, participants will undergo simple anthropometric measurements (weight, height, hip and waist circumference) as well as blood pressure assessment.
This procedure will be repeated after four weeks with a second oil, and four weeks later with the third one, so that all participants will have consumed all three oils.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Low erythrodiol dose
Other: Medium erythrodiol dose
Other: High erythrodiol dose
Low erythrodiol dose
Medium erythrodiol dose
High erythrodiol dose
Plasma erythrodiol concentration
Time frame: 4 months since the last intervention session
Plasma triglyceride concentration
Time frame: 4 months since the last intervention session
Inflammation marker concentration in plasma
Time frame: 4 months since the last intervention session
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Jun 2026, 4 months later.
Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spanish National Research Council